COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK BASED ON EMPA-REG OUTCOME DATA

被引：10
|
作者：
Daacke, I [1 ]
Kandaswamy, P. [2 ]
Tebboth, A. [3 ]
Kansal, A. [4 ]
Reifsnider, O. [4 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim UK, Bracknell, Berks, England
[4] Evidera, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1876
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB46
引用
收藏
页码：A673 / A673
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE®) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN TURKEY BASED EMPA-REG OUTCOME DATA
    Oksuz, E.
    Malhan, S.
    Kamaci, E.
    Urganci, B.
    Tetik, E.
    Temizhan, A.
    Ersoy, R.
    Balbay, Y.
    VALUE IN HEALTH, 2017, 20 (09) : A479 - A479
  • [2] Long-Term Economic Outcomes of Empagliflozin (Jardiance) Treatment in Type 2 Diabetes Mellitus (T2DM) based on the EMPA-REG Outcome Trial
    Kansal, Anuraag R.
    Zheng, Ying
    Proskorovsky, Irina
    Reifsnider, Odette
    Kandaswamy, Prashanth
    Ruffolo, Antonio
    DIABETES, 2016, 65 : A326 - A326
  • [3] Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure
    Reifsnider, Odette S.
    Kansal, Anuraag R.
    Franke, Jennifer
    Lee, Joseph
    George, Jyothis T.
    Brueckmann, Martina
    Kaspers, Stefan
    Brand, Sarah B.
    Ustyugova, Anastasia
    Linden, Stephan
    Stargardter, Matthew
    Hau, Nikco
    ESC HEART FAILURE, 2020, 7 (06): : 3910 - 3918
  • [4] Cost-Effectiveness Analysis of Empagliflozin Treatment in Patients With Type 2 Diabetes and Chronic Heart Failure Based on Subgroup of EMPA-REG OUTCOME
    Reifsnider, Odette S.
    Kansal, Anuraag
    Franke, Jennifer
    Lee, Joseph
    George, Jyothis T.
    Brueckmann, Martina
    Kaspers, Stefan
    Brand, Sarah
    Ustyugova, Anastasia
    Linden, Stephan
    Gandhi, Pranav
    CIRCULATION, 2018, 138
  • [5] Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial
    Kansal, A.
    Reifsnider, O. S.
    Proskorovsky, I.
    Zheng, Y.
    Pfarr, E.
    George, J. T.
    Kandaswamy, P.
    Ruffolo, A.
    DIABETIC MEDICINE, 2019, 36 (11) : 1494 - 1502
  • [6] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM
    Reifsnider, O.
    Kansal, A.
    Franke, J.
    Lee, J.
    George, J. T.
    Brueckmann, M.
    Kaspers, S.
    Brand, S.
    Ustyugova, A.
    Linden, S.
    Hau, N.
    VALUE IN HEALTH, 2018, 21 : S128 - S128
  • [7] EMPA-REG OUTCOME: A Milestone in the Treatment of the Diabetes mellitus Type 2?
    Schneider, C. A.
    Pfuetzner, A.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (06): : 405 - 407
  • [8] IMPACT OF EMPAGLIFLOZIN (JARDIANCE) TO THE NHS: ESTIMATION OF BUDGET AND EVENT IMPACT BASED ON EMPA-REG OUTCOME DATA
    Daacke, I
    Kandaswamy, P.
    Tebboth, A.
    Kansal, A.
    Reifsnider, O.
    VALUE IN HEALTH, 2016, 19 (07) : A668 - A668
  • [9] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [10] Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
    Bernard Zinman
    Silvio E. Inzucchi
    Christoph Wanner
    Uwe Hehnke
    Jyothis T. George
    Odd Erik Johansen
    David Fitchett
    Diabetologia, 2018, 61 : 1522 - 1527
12345